andyworks / iStockphoto.com
In the current IP landscape it is wise to be prepared for attacks on important patents, as Lars Kellberg, corporate vice president and corporate patents of Novo Nordisk, explains to LSIPR.
According to Lars Kellberg, corporate vice president and corporate patents of Novo Nordisk, the company is always prepared to combat a patent attack. Since the introduction of the inter partes review (IPR) system in the US, the company has had to reconsider its approach to protecting its innovations because, in its opinion, the IPR is weakening the patent system.
“Although the IPR is a new mechanism, the statistics already show that the likelihood of surviving an IPR is surprisingly low,” says Kellberg.
“This is especially surprising when you take into consideration that the US Patent and Trademark Office (USPTO) has carried out a thorough examination of the patent.”
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
LSIPR 50 2017, Lars Kellberg, Novo Nordisk, inter partes review, IPR, US Patent and Trademark Office,